RxDoctor Payments Data

Melissa McGuire

Family · Greenfield, WINPI 1215992979

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,898 of the $5,472 with a category attached, or 89.5%. 23 manufacturers reported payments, led by Sun Pharmaceutical Industries Inc. at 29.8% of the total. Among family clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,472in general payments, 2019–2025

Across 392 payments — averaging $13.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$2K
  • AbbVie$1K
  • Johnson & Johnson$470
  • UCB, Inc.$407
  • Arcutis Biotherapeutics, Inc.$291
  • Regeneron Healthcare Solutions, Inc.$165
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$4,89890%
  • Education$57410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,472 in reported general payments places this provider in the 95th percentile of 1,273 family providers in Wisconsin.

See all family providers in Wisconsin

Medicare billing

Part B allowed, 2024
$81,385
Medicare patients
79
Services billed
859

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab26$99,501
Dupixent PenDupilumab19$71,714
OpzeluraRuxolitinib Phosphate21$44,404
JubliaEfinaconazole12$8,903
Pimecrolimus16$4,472
Clobetasol Propionate57$1,880
Clindamycin Phosphate25$1,099
Tretinoin11$995
Metronidazole14$781
Hydrocortisone34$588
Doxycycline Hyclate25$564
Ciclopirox12$557
Ketoconazole44$528
Triamcinolone Acetonide39$397
ValacyclovirValacyclovir Hcl12$390

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$163$44,40421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,273 family providers in Wisconsin.

Other family in Greenfield

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →